To access this material please log in or register

Register Authorize

Effect of cardiac resynchronization therapy on the time course of ventricular tachycardia in patients with dilated cardiomyopathy and severe heart failure

Lebedev D. I., Minin S. M., Krivolapov S. N.

Keywords: dilatation, ventricular rhythm disorder, cardiomyopathy, resynchronization therapy

DOI: 10.18087/rhfj.2014.1.1919

Background. Despite improved survival rate provided by new pharmaceuticals, 5year survival of patients diagnosed with HF is 50 % and most of fatal outcomes occur suddenly and unpredictably. Aim. To study the effect of cardiac resynchronization therapy (CRT) on the course of ventricular tachycardia in patients with dilated cardiomyopathy (DCMP) and to analyze a possibility for using radionuclide methods for predicting the development of life-threatening arrhythmias during the treatment. Materials and methods. The study included 70 patients with DCMP aged from 32 to 75 years (55±12 years), NYHA FC III CHF, LV EF 30.1±3.8 %, 6min walk distance 290.5±64.3 m, and end-diastolic volume (EDV) 220.7±50.9 ml. 34hour ECG monitoring was performed for all patients prior to and at one year of CRT. The first group included 35 (50 %) patients with paroxysmal ventricular tachycardia (VT); the second group included 35 (50 %) patients without VT episodes. CRT devices with defibrillation option were implanted to all patients. Results. In one year, positive clinical changes were observed in all patients: LV EF increased to 42.8±4.8 % (p≤0.001); HF FC decreased to FC II; 6min walk distance increased to 377.2±45.3 m (p≤0.001); and LV EDV reduced to 197.9±47.8 ml (p≤0.005). 28 (80 %) patients had no VT episodes over one year; 7 (20 %) patients had unstable VT episodes. Patients with an increase in EF by 14 % and a decrease in EDV by 35 ml did not have any VT episodes over the year. In patients who still had paroxysmal VT during the study, EF was increased by 9 % and EDV was reduced only by 13 ml. The second stage of study included evaluation of the effect of CRT-induced changes in myocardial metabolic defect (MMD) on possible development of VT episodes. Patients with the CRT-induced decrease in MMD to below 15 % did not have VT episodes; when post-treatment MMD exceeded 15 %, the patients had episodes of paroxysmal VT. Conclusion. Effective CRT statistically significantly reduces the number of VT episodes in patients with DCMP. The improvement in fatty acid metabolism resulting from CRT provides a decrease in the number of VT episodes.
  1. Levy D, Kenchaiah S, Larson MG et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347 (18):1397–1402.
  2. Johnson RA, Palacios I. Dilated cardiomyopathies of the adult (first of two parts). N Engl J Med. 1982;307 (17):1051–1058.
  3. MERIT-HF study group. Effect of metoprolol CR / XL in chronic heart failure: Metoprolol CR / XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353 (9169):2001–2007.
  4. Cleland JG, Daubert JC, Erdmann E et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J. 2006;27 (16):1928–1932.
  5. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
  6. Faran A, Lewicka-Nowak E, Dabrowska-Kugacka A et al. Cardiac resynchronisation therapy in patients with endstage heart failure – long-term follow-up. Kardiol Pol. 2008;66 (1):19–26.
  7. McAlister FA, Ezekowitz JA, Wiebe N et al. Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med. 2004;141 (5):381–390.
  8. Bax JJ, Abraham T, Barold SS et al. Cardiac resynchronization therapy: Part 1--issues before device implantation. J Am Coll Cardiol. 2005;46 (12):2153–2167.
  9. Bax JJ, Abraham T, Barold SS et al. Cardiac resynchronization therapy: part 1 – issues before device implantation; Part 2 – Issues During and After Device Implantation and Unresolved Questions. J Am Coll Cardiol. 2005;46 (12):2168–2182.
  10. Bristow M, Saxon L, Boehmer J et al. Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac – resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004 May 20;350 (21):2140–2150.
  11. Cleland JG, Daubert JC, Erdmann E et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352 (15):1539–1549.
  12. Kies P, Bax JJ, Molhoek SG et al. Effect of cardiac resynchronization therapy on inducibility of ventricular tachyarrhythmias in cardiac arrest survivors with either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2005;95 (9):1111–1114.
  13. Garrigue S, Barold SS, Hocini M et al. Treatment of drug refractory ventricular tachycardia by biventricular pacing. Pacing Clin Electrophysiol. 2000;23 (11 Pt 1):1700–1702.
  14. Thackray S, Coletta A, Jones P et al. Clinical trials update: Highlights of the Scientific Sessions of Heart Failure 2001, a mee­ting of the Working Group on Heart Failure of the European Society of Cardiology. CONTAK-CD, CHRISTMAS, OPTIME-CHF. Eur J Heart Fail. 2001;3 (4):491–494.
  15. Arya A, HaghjooM, Dehghani MR et al. Effect of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in patients with an implantable cardioverter-defibrillator. Heart Rhythm. 2005;2 (10):1094–1098.
  16. Befeler B, Berkovits BV, Aranda JM et al. Programmed simultaneous biventricular stimulation in man, with special reference to its use in the evaluation of intraventricular reentry. Eur J Cardiol. 1979;9 (5):369–378.
  17. Ermis C, Seutter R, Zhu AX et al. Impact of Upgrade to Cardiac Resynchronization Therapy on Ventricular Arrhythmia Frequency in Patients With Implantable Cardioverter-Defibrillators. J Am Coll Cardiol. 2005;46 (12):2258–2263.
  18. Higgins SL, Hummel JD, Niazi IK et al. Cardiac resynchronization therapy for the treatment of heart failure patients with intraventri­cular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol. 2003;42 (8):1454–1459.
  19. Young JB, Abraham WT, Smith AL et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA. 2003;289 (20):2685–2694.
  20. Bradley DJ, Bradley EA, Baughman KL et al. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA 2003;289 (6):730–740.
  21. Ovsyshcher IE, Auricchio A. Cardiac resynchronization therapy for heart failure shows great promise. Isr Med Assoc J. 2003;5 (8):589–591.
  22. Medina-Ravell VA1, Lankipalli RS, Yan GX et al. Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization. Does resynchronization therapy pose a risk for patients predisposed to long QT or torsade de pointes? Circulation. 2003;107 (5):740–746.
  23. Бугрий М. Е., Сергиенко В. Б. Роль радионуклидной 4D-томо­ветри­кулографии в диагностике нарушений насосной функции сердца. Радиология-практика. 2009;4:18–33.
  24. Лишманов Ю. Б., Чернов В. И., Кривоногов Н. Г. и др. Радио­нуклидные методы исследования в диагностике сердечно-сосудистых заболеваний. Сибирский медицинский журнал. 2010;25 (4):8–13.
  25. Tamaki N, Yoshinaga K. Novel iodinated tracers, MIBG and BMIPP, for nuclear cardiology. J Nucl Cardiol. 2011;18 (1):135–143.
  26. Дощицын В. Л. Внезапная аритмическая смерть и угрожающие аритмии. Российский кардиологический журнал. 1999;1:46–51.
  27. Zecchin M, Sinagra G. Primary prevention of sudden death in dila­ted cardiomyopathy. Italian Heart J. 2004;5 (Suppl 1):81S-82S.
  28. Kies P, Molhoek SG, Bax JJ el al. Cardiac resynchronization therapy results in a lower arrhythmia burden [abstract]. J Coll Cardiol. 2004;43 (Suppl A): 149A.
  29. Adamson PB1, Kleckner KJ, VanHout WL et al. Cardiac resynchronization therapy improves heart rate variability in patients with symptomatic heart failure. Circulation. 2003;108 (3):266–269.
  30. Livanis EG1, Flevari P, Theodorakis GN et al. Effect of biventricular pacing on heart rate variability in patients with chronic heart failure. Eur J Heart Fail. 2003;5 (2):175–178.
  31. Guerra JM1, Wu J, Miller JM, Groh WJ. Increase in ventricular tachycardia frequency after biventricular implantable cardioverter defibrillator upgrade. J Cardiovasc Electrophysiol. 2003;14 (11):1245–1247.
  32. Di Cori A1, Bongiorni MG, Arena G et al. New-onset ventricular tachycardia after cardiac resynchronization therapy. J Interv Card Electrophysiol. 2005;12 (3):231–235.
  33. Kjekshus JK. Mechanism for flow distribution in normal and ische­mic myocardium during increased ventricular preload in the dog. Circ Res. 1973;33 (5):489–499.
  34. Uebleis C1, Ulbrich M, Tegtmeyer R et al. Electrocardiogram-gated 18F-FDG PET / CT hybrid imaging in patients with unsatisfactory response to cardiac resynchronization therapy: initial clinical results. J Nucl Med. 2011;52 (1):67–71.
  35. Sundell J1, Engblom E, Koistinen J et al. The effects of cardiac resynchronization therapy on left ventricular function, myocardial energetics, and metabolic reserve in patients with dilated cardiomyopathy and heart failure. J Am Coll Cardiol. 2004;43 (6):1027–1033.
Lebedev D. I., Minin S. M., Krivolapov S. N. Effect of cardiac resynchronization therapy on the time course of ventricular tachycardia in patients with dilated cardiomyopathy and severe heart failure. Russian Heart Failure Journal. 2014;15(1):39–44

To access this material please log in or register

Register Authorize
Ru En